Literature DB >> 1977104

Dopaminergic agonists in the treatment of Parkinson's disease.

C G Goetz1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1977104

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  8 in total

1.  Neuropharmacology of dopamine receptors:: Implications in neuropsychiatric diseases.

Authors:  F I Tarazi
Journal:  J Sci Res Med Sci       Date:  2001-10

Review 2.  Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease.

Authors:  R G Fariello
Journal:  Drugs       Date:  1998       Impact factor: 9.546

3.  Comparative Review of Dopamine Receptor Agonists in Parkinson's Disease.

Authors:  R J Uitti; J E Ahlskog
Journal:  CNS Drugs       Date:  1996-05       Impact factor: 5.749

4.  Use of the dopamine receptor agonist Mirapex in the treatment of Parkinson's disease.

Authors:  N V Fedorova; I P Chigir'
Journal:  Neurosci Behav Physiol       Date:  2007-07

5.  Integrated dopaminergic neuronal model with reduced intracellular processes and inhibitory autoreceptors.

Authors:  Maell Cullen; KongFatt Wong-Lin
Journal:  IET Syst Biol       Date:  2015-12       Impact factor: 1.615

Review 6.  Bromocriptine/levodopa combined versus levodopa alone for early Parkinson's disease.

Authors:  J J van Hilten; C C Ramaker; Rl Stowe; N J Ives
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17

7.  Effects of acute administration of DA agonists on locomotor activity: MPTP versus neonatal intracerebroventricular 6-OHDA treatment.

Authors:  Trevor Archer; Tomas Palomo; Robert McArthur; Anders Fredriksson
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.978

Review 8.  Clinical pharmacology of dopamine agonists in Parkinson's disease.

Authors:  K W Lange
Journal:  Drugs Aging       Date:  1998-11       Impact factor: 4.271

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.